Global 3D Cell Culture Market Research Report – Forecast to 2023

$4450$6250

SKU: 180417 Category: Tag:

Description

The cell culture technique is present in biological areas for the development of drug discovery, regenerative medicine, and protein production. The cell culture technique has evolved from 2D cell culture to 3D cell culture. The 3D culture resembles physiological conditions closely and has various different advantages over the 2D culture conditions. The 3D cell culture can be defined as the culture of living cells within micro-assembled devices and supports the display of three-dimensional structures mimicking tissue and organ-specific microarchitecture.
The factors driving the market include increasing application of biotech and pharmaceutical companies and hospitals and rise in the patient population affected by cancer. The growing number of patients in need of organ transplantation is propelling the growth of the market. However, the high cost of devices, regulatory framework, and lack of awareness amongst the masses are major challenges for the market.
The global market for 3D cell culture is segmented on the basis of technique, product, application, end user, and region. On the basis type of technique, it is segmented into scaffold-based 3D cell culture and scaffold-free 3D cell culture. The scaffold-based 3D cell culture is further segmented into hydrogel-based support and polymeric hard material based support. The scaffold-free 3D cell culture is further segmented into hanging drop microplates, spheroid microplates containing ultra-low attachment (ULA) coating, and microfluidic 3D cell culture. On the basis of product, it is segmented into consumables and instruments. The consumables are further segmented into culture media, reagents, 3D multi-well plates, and glassware. The instruments are further segmented into bioreactor, flow cytometer, and cell culture chips. On the basis of application, it is segmented into drug discovery, cancer research, stem cell research, tissue screening and engineering, and regenerative medicine. On the basis of end users, it is segmented into pharmaceutical and biotechnology companies, contract research organizations, and research and academic laboratories.
The global 3D cell culture market accounted for USD 725.15 million in 2016 and is expected to register a CAGR of 25.50% over the forecast period.
Key Players
Thermo Fisher Scientific Inc., Lonza, Corning Incorporated, Kuraray Co Ltd, Becton, Dickinson and Company, Merck KGaA, Charles River Laboratories Inc., Tecan Trading AG, ReproCELL Europe Ltd, The Electrospinning Company, Lena Biosciences, Inc., InSphero, Global Cell Solutions Inc., Synthecon, Inc., and 3D Biotek LLC.
Study objectives
• To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global 3D cell culture market
• To provide insights into factors influencing and affecting the market growth
• To provide historical and forecast revenue of market segments and sub-segments with respect to countries
• To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market
• To provide economic factors that influence the global 3D cell culture market
• To provide a detailed analysis of the value chain and supply chain of the global 3D cell culture market

Target Audience
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Academic Institutes and Universities
• Potential Investors

Key Findings
• The global 3D cell culture market is expected to reach USD 3555.77 million by 2023 at a CAGR of 25.50 %
• On the basis of technique, the scaffold-based 3D cell culture is the largest segment which is projected to register a CAGR of 25.81% during the forecast period from 2017 to 2023
• On the basis of product, consumables are expected to account for the largest market share of 25.88% during the forecast period from 2017 to 2023
• On the basis of application, drug discovery is projected to register a CAGR of 25.75% during the forecast period from 2017 to 2023
• On the basis of end user, pharmaceutical and biotechnology companies captured the largest market globally and are expected to reach USD 1398.35 million by 2023
• On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas holds the largest share of the global 3D cell culture market which is expected to reach USD 1318.73 million by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 26.17% from 2017 to 2023
Regional Analysis
• Americas
o North America
 US
 Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

  1 Report Prologue 2 Market Introduction 2.1 Definition 2.2 Scope of the Study 2.3 Research Objective 2.4 Assumptions & Limitations 2.4.1 Assumptions 2.4.2 Limitations 2.4.3 Market Structure 3 Research Methodology 3.1 Primary Research Methodology 3.2 Secondary Research Methodology 3.3 Market Size Estimation 3.4 Forecast Model 4 Market Dynamics 4.1 Introduction 4.2 Drivers 4.2.1 Increasing application of biotech & pharmaceutical companies and hospitals 4.2.2 The rise in the patient population affected by cancer 4.2.3 Growing number of patients in need for organ transplantation 4.3 Restraints 4.3.1 High cost of devices and regulatory framework 4.4 Opportunity 4.4.1 Entering untapped markets 4.5 Mega Trend 4.5.1 Increasing use of 3D cell culture in cancer and stem cell research 4.6 Macroeconomics 4.7 Technological Trends 5 Market Factor Analysis 5.1 Value Chain Analysis 5.1.1 Drug discovery/research 5.1.2 Clinical and pre-clinical trials 5.1.3 Manufacturing 5.1.4 Sales and distribution 5.2 Porter’s Five Forces Model 5.2.1 Bargaining Power of Suppliers 5.2.2 Bargaining Power of Buyers 5.2.3 The threat of New Entrants 5.2.4 Threat of Substitutes 5.2.5 Intensity of Rivalry 5.3 Investment Opportunities 5.4 Pricing Analysis 5.5 Demand & Supply: Gap Analysis 6 Global 3D Cell Culture Market, By Technique 6.1 Introduction 6.2 Scaffold Based 3D Cell Culture 6.2.1 Hydrogel-based support 6.2.2 Polymeric hard material based support 6.3 Scaffold Free 3D Cell Culture 6.3.1 Hanging Drop Microplates 6.3.2 Spheroid Microplates containing Ultra-Low Attachment (ULA) Coating 6.3.3 Microfluidic 3D Cell Culture 7 Global 3D Cell Culture Market, By Product 7.1 Introduction 7.2 Consumables 7.2.1 Culture Media 7.2.2 Reagents 7.2.3 3D Multiwell Plates 7.2.4 Glassware 7.3 Instruments 7.3.1 Bioreactor 7.3.2 Flow Cytometer 7.3.3 Cell Culture Chips 8 Global 3D Cell Culture Market, By Application 8.1 Introduction 8.2 Drug Discovery 8.3 Cancer Research 8.4 Stem Cell Research 8.5 Tissue Screening & Engineering 8.6 Regenerative Medicine 9 Global 3D Cell Culture Market, By End User 9.1 Introduction 9.2 Pharmaceutical & Biotechnology Companies 9.3 Contract Research Organizations 9.4 Research & Academic Laboratories 10 Global 3D Cell Culture Market, By Region 10.1 Americas 10.1.1 North America 10.1.1.1 U.S. 10.1.1.2 Canada 10.1.2 South America 10.2 Europe 10.2.1 Western Europe 10.2.1.1 Germany 10.2.1.2 France 10.2.1.3 U.K. 10.2.1.4 Italy 10.2.1.5 Spain 10.2.1.6 Rest of Western Europe 10.2.2 Eastern Europe 10.3 Asia Pacific 10.3.1 Japan 10.3.2 China 10.3.3 India 10.3.4 Australia 10.3.5 Republic of Korea 10.3.6 Rest of Asia Pacific 10.4 Middle East & Africa 10.4.1 United Arab Emirates 10.4.2 Saudi Arabia 10.4.3 Oman 10.4.4 Kuwait 10.4.5 Qatar 10.4.6 Rest of Middle East & Africa 11 Company Landscape 11.1 Company Share Analysis 12 Company Profiles 12.1 Thermo Fisher Scientific Inc. 12.1.1 Company Overview 12.1.2 Financial Overview 12.1.3 Product Offerings 12.1.4 Key Developments 12.1.5 SWOT Analysis 12.1.6 Key Strategy 12.2 Lonza 12.2.1 Company Overview 12.2.2 Financial Overview 12.2.3 Product Offerings 12.2.4 Key Developments 12.2.5 SWOT Analysis 12.2.6 Key Strategy 12.3 Corning Incorporated 12.3.1 Company Overview 12.3.2 Financial Overview 12.3.3 Product Offerings 12.3.4 Key Developments 12.3.5 SWOT Analysis 12.3.6 Key Strategy 12.4 Kuraray Co Ltd. 12.4.1 Company Overview 12.4.2 Financial Overview 12.4.3 Product Offerings 12.4.4 Key Developments 12.4.5 SWOT Analysis 12.4.6 Key Strategy 12.5 Becton, Dickinson and Company 12.5.1 Company Overview 12.5.2 Financial Overview 12.5.3 Product Offerings 12.5.4 Key Developments 12.5.5 SWOT Analysis 12.5.6 Key Strategy 12.6 Merck KGaA 12.6.1 Company Overview 12.6.2 Financial Overview 12.6.3 Product Offerings 12.6.4 Key Developments 12.6.5 SWOT Analysis 12.6.6 Key Strategy 12.7 Charles River Laboratories Inc. 12.7.1 Company Overview 12.7.2 Financial Overview 12.7.3 Product Offerings 12.7.4 Key Developments 12.7.5 SWOT Analysis 12.7.6 Key Strategy 12.8 Tecan Trading AG 12.8.1 Company Overview 12.8.2 Financial Overview 12.8.3 Product Offerings 12.8.4 Key Developments 12.8.5 SWOT Analysis 12.8.6 Key Strategy 12.9 ReproCELL Europe Ltd 12.9.1 Company Overview 12.9.2 Financial Overview 12.9.3 Product Offerings 12.9.4 Key Developments 12.9.5 SWOT Analysis 12.9.6 Key Strategy 12.1 The Electrospinning Company 12.10.1 Company Overview 12.10.2 Financial Overview 12.10.3 Product Offerings 12.10.4 Key Developments 12.10.5 SWOT Analysis 12.10.6 Key Strategy 12.11 Lena Biosciences, Inc. 12.11.1 Company Overview 12.11.2 Financial Overview 12.11.3 Product Offerings 12.11.4 Key Developments 12.11.5 SWOT Analysis 12.11.6 Key Strategy 12.12 InSphero 12.12.1 Company Overview 12.12.2 Financial Overview 12.12.3 Product Offerings 12.12.4 Key Developments 12.12.5 SWOT Analysis 12.12.6 Key Strategy 12.13 Global Cell Solutions Inc. 12.13.1 Company Overview 12.13.2 Financial Overview 12.13.3 Product Offerings 12.13.4 Key Developments 12.13.5 SWOT Analysis 12.13.6 Key Strategy 12.14 Synthecon, Inc. 12.14.1 Company Overview 12.14.2 Financial Overview 12.14.3 Product Offerings 12.14.4 Key Developments 12.14.5 SWOT Analysis 12.14.6 Key Strategy 12.15 3D Biotek LLC. 12.15.1 Company Overview 12.15.2 Financial Overview 12.15.3 Product Offerings 12.15.4 Key Developments 12.15.5 SWOT Analysis 12.15.6 Key Strategy 13 Conclusion 13.1 Key Findings 13.1.1 The CEO’s Viewpoint 13.1.2 Unmet Needs 13.1.3 Key Companies to Watch 13.1.4 Prediction of 3D cell culture Industry 14 Apendix 14.1 Discussion Blue Print 14.2 References